サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1301033

臨床腫瘍学次世代シーケンシング市場規模、シェア、動向分析レポート：ワークフロー別（NGSプレシーケンス、NGSデータ解析）、技術別、用途別、最終用途別、地域別、セグメント予測、2023年～2030年

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
臨床腫瘍学次世代シーケンシング市場規模、シェア、動向分析レポート：ワークフロー別（NGSプレシーケンス、NGSデータ解析）、技術別、用途別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月14日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臨床腫瘍学次世代シーケンシング市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の臨床腫瘍学次世代シーケンシング市場規模は2030年までに11億6,000万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 15.7％で拡大すると予測されています。臨床腫瘍学次世代シーケンシング（NGS）市場は需要が高いです。がんに対する効果的な個別化医療・治療法の開発、NGSの採用増加の引き金となるヘルスケア支出の増加により、予測期間を通じて拡大率が高まると予測されます。

ヘルスケア費用の増加と効果的ながん治療法の登場は、予測期間中の市場成長を促進すると予想されます。JAMAネットワークが2023年2月に発表した研究では、がん治療費は2020～2030年の30年間で世界全体で最大25兆米ドルに達すると推定されています。がんの総経済支出に占める治療費の比較寄与度は、低所得国よりも高所得国の方が大きいことが判明しました。さらに、がんの診断と治療のために、さまざまな治療技術が開発・利用されています。Wiley社が2023年1月に発表した研究によると、新たな診断技術の開発に利用されている技術的進歩には、画像再構成ソフトウェア、画像診断装置、ハードウェア、バイオマーカー、人工知能アルゴリズムなどがあり、これにより腫瘍の信頼性の高い分析と診断が実現されています。

さらに、予測期間中の臨床腫瘍学次世代シーケンシング市場の成長は、単一遺伝子検査よりもNGSの採用が増加していることが後押ししています。多くの研究が、NGSは単一遺伝子検査よりも費用対効果が高く効率的であることを実証しています。例えば、JCO Precision Oncologyが2023年3月に発表した研究では、スペインのリファレンスセンターでNSCLC患者を診断するためにNGSを採用することは、単一遺伝子検査よりも費用対効果の高い戦略であると結論付けています。さらに、2023年1月にNational Library of Medicineが行った研究では、逐次単一遺伝子検査よりも現在のNGSの方が年間コストをわずかに削減できることが示唆されています。しかし、SSG検査よりもNSG検査を採用することで、平均納期を短縮することができ、ゲノム変化の迅速な同定と日本における小細胞肺がん患者の早期治療開始が容易になります。このような要因が、予測期間中、市場を牽引すると予想されます。

臨床腫瘍学次世代シーケンシング市場レポートハイライト

  • ワークフロー分野では、技術進歩およびがんシーケンスプロジェクトの増加により、NGSシーケンスが2022年の売上高シェア56.0%で市場を独占
  • 技術別では、2022年の臨床腫瘍NGS市場において、ターゲットシーケンスおよびリシーケンスが72.7%の最大収益シェアを占めました。これは、標的化パネルの臨床的有用性の高まりとがん腫瘍の検出効率の高さに起因しています。
  • 用途別では、スクリーニング分野が2022年に80.1%の最高シェアを占めました。このセグメントの優位性は、世界のがん有病率の増加別ものです。
  • 最終用途別では、臨床腫瘍NGS市場において2022年にラボ部門が64.1%の最大シェアを占めました。これは、研究開発活動の増加に起因しています。
  • 北米は2022年に48.68%の最大市場シェアを占めました。同地域の優位性は、同市場における著名な国際的プレイヤーの存在と、同地域におけるライフサイエンス研究＆ソリューション開発への公的機関および民間機関からの投資増加別ものです。

目次

第1章 調査手法と範囲

  • 情報調達
  • 情報またはデータ分析
  • 市場範囲とセグメントの定義
  • 市場モデル
    • 企業市場シェア別の市場調査
    • 地域分析

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • セグメントのスナップショット
  • 競合情勢のスナップショット

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • SWOT分析：要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • 普及と成長の見通しマッピング、2022年
  • COVID-19の影響分析

第4章 臨床腫瘍学次世代シーケンシング市場の分類：技術推定・動向分析

  • 臨床腫瘍NGS市場：技術変動分析
  • テクノロジー別
  • 全ゲノム配列決定
    • 臨床腫瘍市場向け全ゲノムシークエンシング、2018～2030年（100万米ドル）
  • 全エクソームシーケンス
    • 臨床腫瘍市場向け全エクソームシーケンシング、2018～2030年（100万米ドル）
  • ターゲットシーケンシングとリシーケンシング
    • 臨床腫瘍市場向けのターゲットシークエンシングおよびリシークエンシング、2018～2030年（100万米ドル）

第5章 臨床腫瘍学次世代シーケンシング市場の分類：ワークフローの推定・動向分析

  • 臨床腫瘍NGS市場：ワークフロー変動分析
  • ワークフロー別
  • NGSプリシーケンス
    • 臨床腫瘍学市場向けのNGS事前シーケンス、2018～2030年（100万米ドル）
  • NGSシーケンス
    • 臨床腫瘍学市場向けのNGSシーケンス、2018～2030年（100万米ドル）
  • NGSデータ解析
    • 臨床腫瘍市場のNGSデータ解析、2018～2030年（100万米ドル）

第6章 臨床腫瘍学次世代シーケンシング市場の分類：用途の推定・動向分析

  • 臨床腫瘍NGS市場：用途変動分析
  • 最終用途別
  • ふるい分け
    • スクリーニング臨床腫瘍NGS市場、2018～2030年（100万米ドル）
    • 散発性がん
    • 遺伝性がん
  • コンパニオン診断
    • コンパニオン診断、臨床腫瘍学 NGS市場、2018～2030年（100万米ドル）
  • その他の診断
    • その他の診断薬臨床腫瘍NGS市場、2018～2030年（100万米ドル）

第7章 臨床腫瘍学次世代シーケンシング市場分類：最終使用推定・動向分析

  • 臨床腫瘍NGS市場：最終用途の変動分析
  • 最終用途別
  • 病院
    • 病院臨床腫瘍NGS市場、2018～2030年（100万米ドル）
  • クリニック
    • クリニック臨床腫瘍学のNGS市場、2018～2030年（100万米ドル）
  • 研究室
    • 研究室の臨床腫瘍NGS市場、2018～2030年（100万米ドル）

第8章 臨床腫瘍学次世代シーケンシング市場の地域ビジネス分析

  • 臨床腫瘍学次世代シーケンシング市場シェア（地域別、2022年および2030年）
  • 北米
    • 北米の臨床腫瘍学次世代シーケンシング市場、2018～2030年（100万米ドル）
    • 米国
    • カナダ
  • 欧州
    • 欧州の臨床腫瘍学次世代シーケンシング市場、2018～2030年（100万米ドル）
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋地域の臨床腫瘍学次世代シーケンシング市場、2018～2030年（100万米ドル）
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカ臨床腫瘍学次世代シーケンシング市場、2018～2030年（100万米ドル）
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • MEAの臨床腫瘍学次世代シーケンシング市場、2018～2030年（100万米ドル）
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 会社の分類
  • 戦略マッピング
  • 企業プロファイル・一覧表
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Partek Incorporated
    • Foundation Medicine Inc.
    • Oxford Nanopore Technologies
    • Paradigm Diagnostics, Inc.
    • Caris Life Sciences
    • Eurofins Scientific
    • PerkinElmer, Inc.
図表

List of Tables

  • Table 1 Cancer Incidence and Mortality, By Region, 2018
  • Table 2 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
  • Table 3 FDA-Approved NGS Tumor-Profiling Tests for Companion Diagnostics
  • Table 4 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
  • Table 5 North America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 7 North America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 8 North America clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 North America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 12 U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 14 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 15 Canada clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 17 Canada clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 18 Canada clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 20 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 21 Europe clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 24 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 25 Germany clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 Germany clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 27 UK clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 28 UK clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 29 UK clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 30 UK clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 31 France clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 France clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 33 France clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 34 France clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Italy clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 37 Italy clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 38 Italy clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 39 Spain clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 40 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Spain clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 43 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 44 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 45 Denmark clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 47 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 48 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 49 Sweden clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 51 Norway clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 53 Norway clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 59 Japan clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 60 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Japan clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 62 Japan clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 63 China clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 64 China clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 65 China clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 66 China clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 67 India clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 68 India clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 69 India clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 70 India clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 71 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 73 South Korea clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 74 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 75 Australia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 77 Australia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 78 Australia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 79 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 80 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 81 Thailand clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 82 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 83 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 84 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 85 Latin America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 86 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 87 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 88 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 89 Brazil clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 90 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 91 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 Mexico clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 93 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 94 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 95 Argentina clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 97 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 98 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 99 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 105 South Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 106 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 113 UAE clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 114 UAE clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 117 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Penetration & growth prospect mapping for application, 2022
  • Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • Fig. 14 Cost per genome
  • Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • Fig. 16 Number of new cancer cases in the World, 2022
  • Fig. 17 Market restraint relevance analysis (Current & future impact)
  • Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 Strategy framework
  • Fig. 21 Participant categorization
  • Fig. 22 Clinical oncology NGS market: Technology outlook key takeaways
  • Fig. 23 Clinical oncology NGS market: Technology movement analysis
  • Fig. 24 Whole genome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 25 Whole exome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 26 Targeted sequencing and resequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical oncology NGS market: Workflow outlook key takeaways
  • Fig. 28 Clinical oncology NGS market: Workflow movement analysis
  • Fig. 29 NGS Pre-sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 NGS Sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 31 NGS Data analysis for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 32 Clinical oncology NGS market: Application outlook key takeaways
  • Fig. 33 Clinical oncology NGS market: Application movement analysis
  • Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 35 Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 36 Lifetime cancer risks for common cancers
  • Fig. 37 Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 38 Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 39 Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 40 Clinical oncology NGS market: End use outlook key takeaways
  • Fig. 41 Clinical oncology NGS market: End use movement analysis
  • Fig. 42 Hospitals clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 43 Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 44 Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 45 Regional market place: Key takeaway
  • Fig. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
  • Fig. 47 North America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 49 Canada clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 51 Germany clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 52 UK clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 53 France clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 54 Italy clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 55 Spain clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 58 Norway clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 61 China clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 63 India clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East & Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 74 Kuwait clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 75 Key companies profiled
目次
Product Code: GVR-3-68038-791-9

Clinical Oncology Next Generation Sequencing Market Growth & Trends

The global clinical oncology next generation sequencing market size is expected to reach USD 1.16 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.7% from 2023 to 2030. The clinical oncology next generation sequencing (NGS) market is in high demand. It is projected to expand at an increasing rate throughout the forecast period owing to the rising healthcare expenditure triggering the development of effective personalized medicine & therapeutic procedures for cancer and increasing adoption of NGS.

The increasing healthcare expenses and the launch of effective cancer treatments are expected to fuel market growth over the forecast period. A study published by the JAMA network in February 2023 estimated that the cost of cancer treatment can reach up to USD 25 trillion globally over the 30 years from 2020-2030. The comparative contribution of treatment expenses to the total economic expense of cancers was found to be more significant in high-income nations than in low-income nations. Moreover, various treatment techniques are being developed and utilized to diagnose and treat cancer. According to the study published by Wiley in January 2023, technological advances that are being used to develop new diagnostic techniques include image reconstruction software, imaging devices, hardware, biomarkers, and artificial intelligence algorithms, thereby delivering a reliable analysis and diagnosis of the tumor.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is propelled by the rise in the adoption of NGS over single gene testing. Many studies demonstrated that NGS is cost-effective and efficient over single gene testing. For instance, a study published by JCO Precision Oncology in March 2023 concluded that the adoption of NGS in Spanish reference centers to diagnose patients with NSCLC could be a cost-effective strategy over single gene testing. In addition, the study given by the National Library of Medicine in January 2023, suggests that the current NGS over sequential single-gene testing can slightly reduce annual costs. However, embracing NSG over SSG testing can decrease the average turnaround time, facilitating quicker identification of genomic alterations and early initiating therapy for small cell lung cancer patients in Japan. These factors are expected to drive the market over the forecast period.

Clinical Oncology Next Generation Sequencing Market Report Highlights

  • In the workflow segment, NGS sequencing dominated the market with a revenue share of 56.0% in 2022, owing to technological advancements and the rising number of cancer sequencing projects
  • By technology, the targeted sequencing and resequencing accounted for the largest revenue share of 72.7% in the clinical oncology NGS market in 2022. This can be attributed to the growing clinical utility of targeted panels and their efficiency in detecting cancer tumors
  • By application, the screening segment held the highest share of 80.1% in 2022. The segment's dominance is due to the increasing prevalence of cancer worldwide
  • By end-use, the laboratories segment accounted for the largest share of 64.1% in the clinical oncology NGS market in 2022. This can be attributed to the rising number of research and development activities
  • North America held the largest market share of 48.68% in 2022. The dominance of the region is due to the presence of prominent international players in the market and rising investments from public and private organizations in life science research & solutions developments in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Decrease in costs for genetic sequencing
      • 3.2.1.2. Advancements in the field of personalized medicine
      • 3.2.1.3. Rise in competition amongst prominent market entities
      • 3.2.1.4. Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
      • 3.2.1.5. Rise in prevalence of cancer
      • 3.2.1.6. Growing adoption of NGS over single gene testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value based NGS reimbursement policy
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. Penetration and Growth Prospect Mapping, 2022
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 4.1. Clinical Oncology NGS Market: Technology Movement Analysis
  • 4.2. Clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Sequencing & Resequencing
    • 4.5.1. Targeted Sequencing & Resequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 5.1. Clinical Oncology NGS Market: Workflow Movement Analysis
  • 5.2. Clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  • 5.3. NGS Pre-Sequencing
    • 5.3.1. NGS Pre-Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.4. NGS Sequencing
    • 5.4.1. NGS Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Data Analysis
    • 5.5.1. NGS Data Analysis For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 6. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1. Clinical Oncology NGS Market: Application Movement Analysis
  • 6.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 6.3. Screening
    • 6.3.1. Screening Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
    • 6.3.3. Inherited cancer
      • 6.3.3.1. Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.5. Other Diagnostics
    • 6.5.1. Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 7. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 7.1. Clinical Oncology NGS Market: End Use Movement Analysis
  • 7.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 7.5. Laboratories
    • 7.5.1. Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 8. Clinical Oncology Next Generation Sequencing Market Regional Business Analysis

  • 8.1. Clinical Oncology Next Generation Sequencing Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Mexico Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Profiles/Listing
    • 9.3.1. Illumina, Inc.
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific Inc.
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. F. Hoffmann-La Roche Ltd
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Agilent Technologies, Inc.
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Myriad Genetics, Inc.
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Beijing Genomics Institute (BGI)
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. QIAGEN
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Perkin Elmer, Inc.
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. PacBio
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Partek Incorporated
      • 9.3.10.1. Overview
      • 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Foundation Medicine Inc.
      • 9.3.11.1. Overview
      • 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Oxford Nanopore Technologies
      • 9.3.12.1. Overview
      • 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.12.3. Product Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Paradigm Diagnostics, Inc.
      • 9.3.13.1. Overview
      • 9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.13.3. Product Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Caris Life Sciences
      • 9.3.14.1. Overview
      • 9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.14.3. Product Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Eurofins Scientific
      • 9.3.15.1. Overview
      • 9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.15.3. Product Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. PerkinElmer, Inc.
      • 9.3.16.1. Overview
      • 9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.16.3. Product Benchmarking
      • 9.3.16.4. Strategic Initiatives